155 related articles for article (PubMed ID: 8388739)
1. Activated protein C accelerates clot lysis by virtue of its anticoagulant activity.
de Fouw NJ; van Tilburg NH; Haverkate F; Bertina RM
Blood Coagul Fibrinolysis; 1993 Apr; 4(2):201-10. PubMed ID: 8388739
[TBL] [Abstract][Full Text] [Related]
2. Protein C and fibrinolysis: a link between coagulation and fibrinolysis.
de Fouw NJ; Haverkate F; Bertina RM
Adv Exp Med Biol; 1990; 281():235-43. PubMed ID: 2102614
[TBL] [Abstract][Full Text] [Related]
3. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
[TBL] [Abstract][Full Text] [Related]
4. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
[TBL] [Abstract][Full Text] [Related]
5. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
6. The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro.
de Fouw NJ; Haverkate F; Bertina RM; Koopman J; van Wijngaarden A; van Hinsbergh VW
Blood; 1986 Apr; 67(4):1189-92. PubMed ID: 2937472
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S.
de Fouw NJ; de Jong YF; Haverkate F; Bertina RM
Thromb Haemost; 1988 Oct; 60(2):328-33. PubMed ID: 2975409
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
Haskel EJ; Eisenberg PR; Abendschein DR
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
[TBL] [Abstract][Full Text] [Related]
9. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L; Nesheim ME; Tracy PB
Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
[TBL] [Abstract][Full Text] [Related]
10. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
[TBL] [Abstract][Full Text] [Related]
11. 3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
Mukherjee P; Lyden P; Fernández JA; Davis TP; Pryor KE; Zlokovic BV; Griffin JH
Stroke; 2020 Jul; 51(7):2236-2239. PubMed ID: 32568648
[TBL] [Abstract][Full Text] [Related]
12. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
[TBL] [Abstract][Full Text] [Related]
13. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
14. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
15. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
Bajzar L; Kalafatis M; Simioni P; Tracy PB
J Biol Chem; 1996 Sep; 271(38):22949-52. PubMed ID: 8798478
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor.
Lisman T; Adelmeijer J; Nieuwenhuis HK; de Groot PG
Blood Coagul Fibrinolysis; 2003 Sep; 14(6):557-62. PubMed ID: 12960609
[TBL] [Abstract][Full Text] [Related]
17. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
von dem Borne PA; Cox LM; Bouma BN
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1.
Urano T; Castellino FJ; Ihara H; Suzuki Y; Ohta M; Suzuki K; Mogami H
J Thromb Haemost; 2003 Dec; 1(12):2615-20. PubMed ID: 14675098
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro.
Tanaka K; Tawara S; Tsuruta K; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2018 Sep; 24(6):859-866. PubMed ID: 29683037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
